Posterior reversible encephalopathy syndrome during sunitinib therapy.
A case of posterior reversible encephalopathy syndrome (PRES) occurring in a women treated by sunitinib for an ovarian metastatis of a renal cell carcinoma is described. This is the third case described in the literature. The three cases are very similar except for the delay to onset of the PRES (one week to five months). Both antiangiogenic and prohypertensive effects of sunitinib are probably involved in the pathophysiology of PRES. Physicians should be aware of this potentially life-threatening side-effect of sunitinib easily controlled by withdrawing sunitinib and symptomatic treatment.
Service de neurologie, hôpital Delafontaine, 2, rue du Dr-Delafontaine, 93200 Saint-Denis, France.
R
R
Cumurciuc
L
L
Martinez-Almoyna
C
C
Henry
H
H
Husson
T
T
de Broucker
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001925:Brain Damage, Chronic / Q000139:chemically induced* / Q000473:pathology / Q000523:psychology; D002292:Carcinoma, Renal Cell / Q000473:pathology; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced / Q000523:psychology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology; D008279:Magnetic Resonance Imaging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000556:secondary; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D013577:Syndrome; D014057:Tomography, X-Ray Computed
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib